BRAINBox Solutions today announced it has entered into an agreement with Prolight Diagnostics to supply its Pyros® instruments and cartridges for use in point-of-care (PoC) delivery of BRAINBox’s TBI diagnostic/prognostic tests for concussion (also known as mTBI or Acute Traumatic Encephalopathy).
Innovative Offerings from BRAINBox Solutions
“This agreement is an important step towards commercialization of our solutions and reflects the successful progress of our collaboration with Prolight. We look forward to continuing our joint efforts as we prepare for the market launch of our BRAINBox TBI tests and broader adoption of our neurology portfolio,” said Donna J. Edmonds, CEO of BRAINBox Solutions. “The Prolight alliance is part of our broader strategy to deliver TBI and other neurology tests through a portfolio of technologies that enable testing in a variety of settings, including hospital laboratories, clinics, ambulances, emergency departments, nursing homes, and athletic facilities. Our approach also focuses on the commitment and ability to quickly scale to meet this important clinical need and extremely large market opportunity.”
The supply agreement follows a successful collaboration, including a feasibility study in which Prolight evaluated 260 patient samples from the data set of BrainBox’s HeadSMART II pivotal trial on the Psyros platform using three assays for concussion. The results demonstrated excellent performance. Prolight’s Pyros technology enables the rapid detection and measurement of single molecules from a drop of blood. Their proprietary and multiplex-capable technology enables the measurement of biomarkers at extremely low concentrations (single digit ng/L).
The company continues to enhance and expand its patent coverage across highly specific and sensitive biomarkers and neurocognitive testing for TBI and neurodegenerative diseases, both alone and in conjunction with advanced imaging techniques. In particular, the Company recently filed for new international patents differentiating acute and chronic TBI in geriatric patients from neurodegenerative diseases and disorders. After securing patent coverage for use of the sST2 biomarker in TBI and neurodegenerative disease testing, the company continues to enhance the breadth and depth of its intellectual property portfolio in these areas.
